Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS3005 in Advanced Solid Tumors
NCT04233060Phase 1Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Jan 2020
- Primary completion
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CS3005 in solid tumor (advanced stage), sponsored by CStone Pharmaceuticals. Primary endpoint: Number of participants with adverse events up to 2 years. Started Jan 2020; status: completed.
02
Drugs
CS3005
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04233060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04233060.